Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Eligibility Age of Moderna COVID Vaccine Lowered to 6 and Older
August 3, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Japan Greenlights Shionogi’s Stable Supply Plan for 2 Cephalosporin Antibiotics
August 2, 2023
- Mitsubishi Tanabe Drops Once-Daily Oral Edaravone Regimen for ALS
August 2, 2023
- Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
- Kaken’s Burn Eschar Remover NexoBrid Now Available in Japan
August 2, 2023
- Lonsurf-Bevacizumab Combo Approved in EU for Colorectal Cancer: Taiho
August 2, 2023
- Astellas’ Zolbetuximab Accepted for Review in China for CLDN18.2 Gastric Cancer
August 2, 2023
- AbbVie Merges Allergan in Japan after Global Acquisition
August 2, 2023
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
- Astellas to Cut 500 More Jobs in Buyout Targeting Commercial Unit
August 2, 2023
- Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
August 1, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Mitsubishi Tanabe Rolls Out Tardive Dyskinesia Drug in Thailand
August 1, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…